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tivitis during July–September 2007. 
Reported treatment included home 
remedies and a nonprescription, local-
ly available, cream containing a sulfa 
drug. Review of municipal hospital 
records during June 1–September 30, 
2007, identiﬁ  ed no additional cases of 
conjunctivitis. After the last case-pa-
tient died, 17 other persons were iden-
tiﬁ  ed with purulent conjunctivitis: 4 at 
the municipal hospital and 13 during 
active case-ﬁ  nding in schools and the 
community. All were treated with oral 
amoxicillin and chloramphenicol optic 
solution, and 76 contacts were treated 
prophylactically with oral rifampin. 
No further suspected BPF cases were 
detected. Test results for acute arbovi-
rus infection and PCR were negative 
for all patients (Table).
This outbreak of highly fatal ill-
ness is clinically compatible with BPF. 
Compatible features included young 
age, antecedent purulent conjunctivitis, 
signs and symptoms (i.e., antecedent 
conjunctivitis, fever 39.5Cº–41.0Cº, 
abdominal pain, nausea, vomiting, 
petechiae or ecchymoses), and high 
case-fatality rate. Epstein-Barr infec-
tion has reportedly produced simi-
lar symptoms (4) but with an illness 
lasting >7 days in contrast to the <24 
hours for our case-patients.
We did not detect H. aegyptius in 
peripheral blood by culture or in se-
rum or CSF by PCR in the 2 surviv-
ing children and in contacts of case-
patients. One reason could be the 
remoteness of the investigation site, 
which resulted in improper sample 
collection, storage, and processing 
in the ﬁ   eld before samples reached 
reference laboratories. Hemaggluti-
nation tests for arboviruses have low 
speciﬁ  city. Therefore, another known 
or novel pathogen could have caused 
these cases.
Timely treatment with antimicro-
bial drugs for patients with suspected 
disease, prophylaxis of contacts, and 
treatment of children with conjunctivi-
tis resulted in no additional cases. In-
tensive surveillance for febrile illness 
preceded by conjunctivitis, immediate 
treatment, contact prophylaxis, and 
appropriate prompt laboratory testing 
are essential for continued control of 
BPF in this region.
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Hepatitis C Virus 
in Blood Donors, 
Brazil
To the Editor: The Fundação 
de Hematologia e Hemoterapia do 
Amazonas is a public health service 
in Manaus, Brazil, that is responsible 
for serologic screening the serum of 
all blood donations in the region. In 
the state of Amazon, 9.0% of donated 
blood is discarded on the basis of se-
rologic  ﬁ   ndings; discarding because 
of hepatitis C virus (HCV) antibod-
ies declined from 1.25% in 1995 to 
0.32% in 2007. The aim of this study 
was to characterize the serologic and 
molecular proﬁ   le of HCV-antibody–
positive blood donors from the Funda-
ção de Hematologia e Hemoterapia do 
Amazonas. 
For the study, 154 donors were 
selected from a routine database of 
voluntary blood donors who had do-
nated from September 2005 through 
April 2007 (82,851 donations). Fresh 
plasma samples were sent to the labo-
ratory in Manaus through the usual 
transportation systems for regular do-
nations; i.e., samples from 27 cities 
are transported by air for ≈2 hours, 
and samples from 21 localities are 
transported by boat or road, all under 
refrigerated conditions.
An in-house standardized nested-
PCR was used to detect HCV RNA (1). 
Genotype assignment was based on 
type-speciﬁ  c motifs on the sequenced 
amplicons delimited by primers HC11/
HC18 from the 5′ untranslated region 
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(2). Viral load was determined by com-
mercial assay (HCV Monitor, Roche 
Molecular Systems, Inc., Branchburg, 
NJ, USA).
 An association was observed be-
tween HCV RNA and donor age; the 
same trend was seen in the ﬁ  rst-time 
blood donor group. Associations be-
tween HCV-RNA detection and gen-
der (p = 0.875) and place of donation 
(p = 0.989) were not signiﬁ  cant. Us-
ing 18–25 years of age as the refer-
ence group, we found that odds ratios 
(ORs) for having HCV viremia were 
higher for those 45–55 years of age 
(OR 8.19, p<0.001) and 35–45 years 
of age (OR 3.49, p = 0.003). 
We observed increasing rates of 
RNA detection according to the signal-
to-cutoff (S/CO) ratio. However, some 
donors had a weak S/CO ratio (between 
1 and 2) with positive nested-PCR tests 
(Figure). Although adopting an S/CO 
ratio as a criterion for referring for fur-
ther testing by recombinant immunob-
lot assay (RIBA) has been advocated 
by some groups (3), our data show that 
this criterion may be misleading and 
would deny a conﬁ  rmatory diagnosis 
by giving false-negative results for 
many persons.
A total of 113 samples were ana-
lyzed by RIBA; among 48 RIBA-reac-
tive samples, 9 (18.8%) were negative 
for HCV RNA in plasma. However, 
because PCR results may sometimes 
be negative for persons who are actu-
ally infected, a single negative PCR 
result should not be relied on as evi-
dence that virus has cleared from plas-
ma. Such patients must be observed 
for years before they may be declared 
cured (4).
Among 97 RIBA-positive or -in-
determinate samples, viral load was 
detectable in only 33 samples: 27 
(81.8%) RIBA-positive samples and 
6 (18.2%) RIBA-indeterminate sam-
ples. Only HCV genotypes 1 (87.1%) 
and 3 (12.9%) were found. Geograph-
ic distribution shows genotypes 1 and 
3 in Manaus and only genotype 1 in 
other Amazon cities. This genotype 
geographic distribution is similar to 
that found for many Brazilian cities 
and Eastern countries and may reﬂ  ect 
the route of HCV introduction into 
the Amazon; the virus was probably 
brought to the Amazon region by Eu-
ropean immigrants and blood-derived 
medicines imported to Brazil. This hy-
pothesis is corroborated by the ﬁ  nding 
of genotype 3 exclusively in Manaus, 
suggesting that this city is the point of 
arrival of HCV and that new strains 
were disseminated from Manaus to 
inner localities. Historical reconstruc-
tion of HCV in Amazon could be at-
tempted by using these isolates as well 
as others from hepatitis patients in the 
region, including genotype 2 (5).
We found a higher-than-expected 
rate of 50% for indeterminate immu-
noblot results among samples that 
were HCV-RNA positive by nested 
PCR. The presence of HCV RNA in 
plasma samples from 70%–75% of 
blood donors with indeterminate im-
munoblot results has also been re-
ported by other groups in Brazil (6,7); 
however, in contrast, other investiga-
tors have reported RNA prevalence in 
such samples to be ≈2.5% (1,8). Inde-
terminate RIBA test results can indi-
cate seroconversion or seroreversion 
or, occasionally, a chronic infection 
when RNA HCV is detected in plasma 
(9,10). To provide better understand-
ing of the meaning of these indetermi-
nate results, ongoing follow-up stud-
ies are examining the immune status 
of these persons.
Our data offer insights for coun-
seling of donors who have repeatedly 
HCV-reactive results. We suggest that 
Amazon region blood banks screen by 
enzyme immunoassay and use molec-
ular testing as the ﬁ  rst supplemental 
test and that immunoblot be applied to 
the remaining HCV-RNA nonreactive 
samples to distinguish between true 
and false anti-HCV carriers. This new 
algorithm would save considerable 
resources currently spent on immuno-
blot-indeterminate persons in addition 
to HCV-RNA reactive persons who do 
not require further testing for conﬁ  r-
mation. Moreover, according to cur-
rent policy, those with false-positive 
results may be reinstated as donors if 
they have negative retesting results af-
ter 6 months.
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Leishmaniasis in 
Chaparé, Bolivia
To the Editor: In Bolivia, most 
cases of leishmaniasis are caused by 
Leishmania (Viannia) braziliensis (1). 
The parasite is transmitted zoonoti-
cally by several sandﬂ  y species and, 
when transmitted to humans, may 
cause cutaneous leishmaniasis (CL), 
and potentially, mucosal leishmaniasis 
(ML) (2).
Data on the prevalence and effects 
of CL in Bolivia have been scarce, 
even though anecdotal and ofﬁ  cial 
reports indicate a dramatic increase 
in the number of human CL cases in 
Bolivia in the past decade (1,3). Also, 
although CL was originally a sylvatic 
disease in Bolivia, some evidence 
indicates that the transmission cycle 
has adapted to the peridomestic habi-
tat. However, this evidence is largely 
based on individual case reports. No 
information is available on parasite 
species, vectors, and reservoirs in such 
a peridomestic transmission cycle.
A preliminary study to guide fu-
ture research focus and assist in im-
mediate leishmaniasis prevention and 
control policy decision making is 
underway in Isiboro-Secure National 
Park, Chaparé, Bolivia. Our objec-
tives were to collect data on the preva-
lence of leishmaniasis in that area and 
evidence for peridomestic Leishmania 
transmission.
A survey was carried out during 
April–July 2007 in 2 communities in 
Isiboro-Secure National Park, San Ga-
briel (16°40′31′′S and 65°37′38′′W) 
and San Julian (16°41′59′′S and 
65°38′10′′W). These 2 communities 
were selected because of local knowl-
edge of disease in the community, 
their moderate degree of urbaniza-
tion (i.e., ≈50% of the communities’ 
houses are clustered around the main 
access road), and the accessibility of 
the sites to the ﬁ  eld team. In this area, 
CL is transmitted from April through 
October.
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